314 related articles for article (PubMed ID: 29149305)
1. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
[TBL] [Abstract][Full Text] [Related]
2. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
4. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
5. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
6. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
Kong WY; Swaminathan R; Irish A
Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
[TBL] [Abstract][Full Text] [Related]
7. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
9. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
Zhou XJ; Zhou FD; Wang SX; Zhao MH
Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
[TBL] [Abstract][Full Text] [Related]
10. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
11. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
12. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Anjum N; Nabi Z; Alam MA
J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
[TBL] [Abstract][Full Text] [Related]
13. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
[TBL] [Abstract][Full Text] [Related]
14. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.
Ruggenenti P; Cravedi P; Sghirlanzoni MC; Gagliardini E; Conti S; Gaspari F; Marchetti G; Abbate M; Remuzzi G
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1652-9. PubMed ID: 18684896
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.
Huang L; Dong QR; Zhao YJ; Hu GC
Int Urol Nephrol; 2021 Jan; 53(1):111-119. PubMed ID: 32944889
[TBL] [Abstract][Full Text] [Related]
17. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
Dahan K; Debiec H; Plaisier E; Cachanado M; Rousseau A; Wakselman L; Michel PA; Mihout F; Dussol B; Matignon M; Mousson C; Simon T; Ronco P;
J Am Soc Nephrol; 2017 Jan; 28(1):348-358. PubMed ID: 27352623
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient.
Gallon L; Chhabra D
Am J Transplant; 2006 Dec; 6(12):3017-21. PubMed ID: 17294527
[TBL] [Abstract][Full Text] [Related]
20. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]